Genome-wide association study identifies genetic loci for self-reported habitual sleep duration supported by accelerometer-derived estimates by Dashti, Hassan S. et al.
ARTICLE
Genome-wide association study identiﬁes genetic
loci for self-reported habitual sleep duration
supported by accelerometer-derived estimates
Hassan S. Dashti 1,2, Samuel E. Jones 3, Andrew R. Wood et al.#
Sleep is an essential state of decreased activity and alertness but molecular factors regulating
sleep duration remain unknown. Through genome-wide association analysis in 446,118 adults
of European ancestry from the UK Biobank, we identify 78 loci for self-reported habitual sleep
duration (p < 5 × 10−8; 43 loci at p < 6 × 10−9). Replication is observed for PAX8, VRK2, and
FBXL12/UBL5/PIN1 loci in the CHARGE study (n= 47,180; p < 6.3 × 10−4), and 55 signals
show sign-concordant effects. The 78 loci further associate with accelerometer-derived sleep
duration, daytime inactivity, sleep efﬁciency and number of sleep bouts in secondary analysis
(n= 85,499). Loci are enriched for pathways including striatum and subpallium development,
mechanosensory response, dopamine binding, synaptic neurotransmission and plasticity,
among others. Genetic correlation indicates shared links with anthropometric, cognitive,
metabolic, and psychiatric traits and two-sample Mendelian randomization highlights a
bidirectional causal link with schizophrenia. This work provides insights into the genetic basis
for inter-individual variation in sleep duration implicating multiple biological pathways.
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S leep is an essential homeostatically regulated state ofdecreased activity and alertness conserved across animalspecies, and both short and long sleep duration associate
with chronic disease and all-cause mortality1,2. Research in model
organisms (reviewed in refs. 3,4) has delineated aspects of the
neural circuitry of sleep–wake regulation5 and molecular com-
ponents including speciﬁc neurotransmitter and neuropeptide
systems, intracellular signaling molecules, ion channels, circadian
clock genes and metabolic and immune factors4, and more
recently phosphorylation of synaptic proteins6, but their speciﬁc
roles and relevance to human sleep regulation are largely
unknown. Prospective epidemiologic studies suggest that both
short (<6 h per night) and long (>9 h per night) habitual self-
reported sleep duration associate with cognitive and psychiatric,
metabolic, cardiovascular, and immunological dysfunction as well
as all-cause mortality compared to sleeping 7–8 h per night7–9.
Furthermore, chronic sleep deprivation in modern society may
lead to increased errors and accidents10. Yet, whether short or
long habitual sleep duration causally contributes to disease
initiation or progression remains to be established.
Habitual self-reported sleep duration is a complex trait with an
established genetic component (twin- and family-based herit-
ability (h2) estimates= 9–45%11–14). Candidate gene sequencing
in pedigrees and functional validation of rare, missense variants
established BHLHE41 (previously DEC2), a repressor of
CLOCK/ARNTL activity, as a causal gene15,16, supporting the role
of the circadian clock in sleep regulation. Previous genome-wide
association studies (GWASs), including a recent GWAS in up to
128,286 individuals, identiﬁed association of common variants at
or near the PAX8 and VRK2 genes, among other signals that have
not yet been replicated13,14,17–19.
Here, we extend GWAS of self-reported sleep duration in UK
Biobank, test for consistency of effects in independent studies of
adults and children/adolescents, determine their impact on
accelerometer-derived estimates, perform pathway and tissue
enrichment to highlight relevant biological processes, and explore
causal relationships with disease traits.
Results
GWAS for self-reported habitual sleep duration. Among UK
Biobank participants of European ancestry (n= 446,118), mean
self-reported habitual sleep duration was 7.2 h (1.1 standard
deviation) per day (Supplementary Table 1). GWAS using
14,661,600 imputed genetic variants identiﬁed 78 loci (P < 5 × 10−8;
Fig. 1a, Supplementary Data 1,2, Supplementary Figure 1a). Indi-
vidual signals exert an average effect of 1.04min (0.34 standard
deviation) per allele, with the largest effect at the PAX8 locus, with
an estimate of 2.44min (0.16 standard error) per allele. The 5% of
participants carrying the most sleep duration-increasing alleles
self-reported 22.2 min longer sleep duration compared to the 5%
carrying the fewest. The 78 loci explained 0.69% of the variance in
sleep duration, and genome-wide single-nucleotide polymorphism
(SNP)-based heritability was estimated at 9.8 (0.1)%. Of the 78
variants, 43 variants passed a more stringent multiple correction
threshold of P < 6 × 10−9 established by permutation testing for a
related sleep trait20.
Sensitivity analyses indicated that the 78 genetic associations
were largely independent of known risk factors (Supplementary
Data 3). Effect estimates at 15/78 loci were attenuated by 15–25%
upon adjustment for frequent insomnia symptoms, perhaps
reﬂecting contribution to an insomnia sub-phenotype with
physiological hyperarousal and objective short sleep duration21
(Supplementary Data 3). Effect estimates at 19/78 were also
slightly attenuated after adjustment of lifestyle factors. No signal
attenuation was observed when accounting for body mass index
(BMI) at rs9940646 at FTO, the established BMI-associated signal
(r2= 0.81 with rs993960922 and where the higher BMI allele
associated with shorter sleep duration). Analysis conditioned on
the lead SNPs in each genomic region identiﬁed 4 secondary
association signals at the VRK2, DAT1 (SLC6A3), DRD2, and
MAPT loci (Supplementary Table 2). Effect estimates were largely
consistent in GWAS excluding shift workers and those with
prevalent chronic and psychiatric disorders (excluding n=
119,894 participants) (Supplementary Data 1, 2, Supplementary
Table 3, Supplementary Figure 1b, 2). GWAS results were similar
for men and women (rg (SE)= 0.989 (0.042); P < 0.001)
(Supplementary Table 4, Supplementary Figure 1c, 1d, 3).
GWAS for self-reported short and long sleep. Separate GWAS
for short (<7 h; n= 106,192 cases) and long (≥9 h; n= 34,184
cases) sleep relative to 7–8 h sleep duration (n= 305,742 controls)
highlighted 27 and 8 loci, respectively, of which 13 were inde-
pendent from the 78 sleep duration loci (Fig. 1b, Supplementary
Data 2,4, Supplementary Table 5, Supplementary Figures 1e, 1f).
Only the PAX8 signal was shared across all three traits, con-
sistently indicating associations between the minor allele and
longer sleep duration. For most long sleep loci, we could exclude
equivalent effects on short sleep based on 95% conﬁdence inter-
vals (CIs) of effect estimates (Supplementary Figure 4, Supple-
mentary Table 5). Sensitivity analyses accounting for factors
potentially inﬂuencing sleep did not alter the results (Supple-
mentary Data 5, Supplementary Table 6).
Replication of sleep duration loci in independent studies. We
tested for independent replication of lead loci in the CHARGE
(Cohorts for Heart and Aging Research in Genomic Epidemiol-
ogy) consortium GWAS of adult sleep duration (n= 47,180 from
18 studies14) and observed replication evidence for individual
association signals at the PAX8, VRK2, and FBXL12/UBL5/PIN1
loci (P < 6.4 × 10−4; Supplementary Data 2,6,7, Supplementary
Figure 5a), and nominal replication (P < 0.05) for 14 additional
loci. Of the 70 loci covered in the CHARGE consortium, 55 signals
showed a consistent direction of effect (binomial P= 6.1 × 10−7),
and a combined weighted genetic risk score (GRS) of the 70 sig-
nals was associated with a 0.66 min (95% CI: 0.54–0.78) longer
sleep per allele (P= 1.23 × 10−25) in the CHARGE con-
sortium (Table 1). Consistently strong genetic correlation was
observed between the CHARGE consortium and UK Biobank
studies (rg (SE)= 1.00 (0.123); P < 0.001; Supplementary Table 7).
In meta-analysis of CHARGE consortium and UK Biobank stu-
dies, 52/70 signals retained GWAS signiﬁcance, and 38/70 signals
passed the more stringent multiple correction threshold of P < 6 ×
10−9 (Supplementary Data 6).
In the childhood/adolescent GWAS for sleep duration from the
EAGLE (EArly Genetics and Lifecourse Epidemiology) consor-
tium19 (n= 10,554), none of the 78 GWAS signals showed
independent replication (all P > 0.05; Supplementary Data 6, 7,
Supplementary Figure 5b). Of the 77 loci covered in the EAGLE
consortium, marginal evidence of association was observed for
the adult sleep duration loci, with 45/77 signals demonstrating
consistent directionality (binomial P= 0.031). For a combined 77
SNP GRS, we observed an effect of 0.16 min (95% CI: 0.02–0.30)
longer sleep per allele (P= 0.03; Table 1). No signiﬁcant overall
genetic correlation was observed with GWAS of adult sleep
duration (rg (SE)= 0.098 (0.076), P= 0.20 with UK Biobank;
Supplementary Table 7). In meta-analysis of all three sleep
duration GWASs, 56/78 signals retained GWAS signiﬁcance, and
40/78 passed the more stringent multiple correction threshold of
P < 6 × 10−9 (Supplementary Data 2, 6, 7, Supplementary
Figure 5c).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08917-4
2 NATURE COMMUNICATIONS |         (2019) 10:1100 | https://doi.org/10.1038/s41467-019-08917-4 | www.nature.com/naturecommunications
Heritability = 9.8 (0.1)% 
2
PAX8
LOC100130100
VRK2
GALNT3
SCN1A
TTC21B
PABPCP2
LOC100133235
SLC8A1
MBOAT2
MAP2
SPOPL
GPD2
NR4A2
1
C1orf94
GJB5
PDE4B
DAB1
DPYD
3
PCCB
PPP2R3A
STAG1
MSL2
BBX,
LOC285205
LOC100128160
FOXP1
IL20RB
NPM1P17
ERC2
4
BANK1
LCORL
LOC645174
PRKG2
CCSER1
6
SCAND3
LOC646160
FAM83B
MEA1
PPP2R5D
SMAD5-AS2
SRF
CUL7
DNPH1
CUL9
MRPL2
TTBK1
RRP36
KLC4
KLHDC3
LOC100129847
LOC100128159
PNRC1
KIFC1, PHF1
SYNGAP1
CUTA
7
FOXP2
MAD1L1
CHCHD3
8
PPP1R3B
LOC100129150
9
ZCCHC7
MRPL41
EHMT1
ARRDC1-AS1
ARRDC1
DPH7
ZMYND19
10
LOC100131719
GPR26
MLLT10
DNAJC1
SKIDA1
EGR2
ADO
FGF8
NFKB2
PITX3
PSD
FBXW4
GBF1
LDB1
BTRC
NOLC1
NPM3
MGEA5
PPRC1 POLL
KCNIP2 CUEDC2
FBXL15
C10ORF76
HPS6
C10orf95
ELOVL3
11
HSD17B12
METT5D1
OR2BH1P
C11orf63
DRD2
PTPRJ
OR4X2
OR4B1
OR4S1
OR4X1
TRPC6
ARCN1
KMT2A
IFT46
TMEM25
LOC729790
LOC646195
BUD13
GRM5
CA10
LOC339209
MYRF
V27 TMEM258
FEN1
FADS1
FADS3
RAB3IL1
FADS2
12
KSR2
MVK
KCTD10
UBE3B
MYO1H
MMAB
14
LOC100128215
PRKD1
NOVA1
ADCK1
FRDAP
RTN1
FNTB
GPX2
MAX
CHURC1
RAB15
15
SEMA6D
16
FTO
GNAO1
RBFOX1
PRKCB
17
LOC644157
LOC644172
PER1
PFAS
SMAD5-AS5
VAMP2
AURKB
ARHGEF15
RANGRF
BORCS6
CTC1,
TMEM107
KRBA2
SLC25A35
CA10
LOC339209
18
TCF4
19
PIN1
OLFM2
20
YWHAB
PABPC1L
a
Short sleep
Sleep duration
b
5
PAM
PPIP5K2
GIN1
C5ORF30
SLC6A3
LOC100132531
LOC285577
FGFR4
V27 SLC34A1
RGS14
LMAN2
PRELID1
NSD1
MXD3
CDC25C
EGR1
ETF1
GFRA3
HSPA9
NME5
CDC23
KIF20A
BRD8
FAM53C
REEP2
KDM3B
SMAD5
SMAD5-AS1
TRPC7
Long sleep
Heritability = 7.9 (0.1)% 
Heritability = 4.7 (0.1)% 
1
CAMTA1
2
PAX8
LOC100130100
5
RAB3C
PDE4D
11
MPZL2
JAML
MPZL3
C11orf63
GUCY2E
16
FTO
17
KIAA1267
LOC644246
1
LMOD1
IPO9
NAV1
SHISA4
DPYD
PDE4B
C1orf94 GJB5
2
PAX8
LOC100130100
LOC647016
LOC100131953
6
ZSCAN12
ZSCAN31
ZKSCAN3
HCRTR2
USP49
LAMA2
3
AMT, APEH, RHOA, DAG1, 
GNAI2, GNAT1, GPX1, HYAL1, 
MST1, MST1R, SEMA3F, 
TCTA, UBA7 USP4, IFRD2, 
SEMA3B, HYAL3 HYAL2, BSN, 
CACNA2D2, IP6K1, RBM6, 
RBM5, TRAIP, NPRL2, 
SLC38A3, CYB561D2, 
TMEM115, RASSF1, TUSC2, 
NAT6, GMPPB, ZMYND10, 
RNF123, CAMKV, NICN1, 
MON1A, LSMEM2, AMIGO3 
FAM212A, ACTBP13
4
SLC39A8
PRKG2
5
SMAD5
SMAD5-AS1
TRPC7
POLS
LOC100130063
PAM
PPIP5K2
GIN1
c5orf30
7
FOXP2
MAD1L1
8
PCMTD1
PXDNL
11
METT5D1
OR2BH1P
NDUFS3
PSMC3
PTPRJ
RAPSN
CELF1
NUP160
FNBP4
MTCH2
KBTBD4
AGBL2
C1QTNF4
15
SEMA6D
16
GNAO1
17
SHISA6
18
TCF4 22
MGAT3
SYNGR
TAB1
–
lo
g 1
0 
(P
)
–
lo
g 1
0 
(P
)
–
lo
g 1
0 
(P
)
0
2
4
6
8
10
12
Chromosome
40
15
10
5
0
15
10
5
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 20 22 23
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 20 22 23
Fig. 1 Plots for genome-wide association analysis results for sleep duration and short/long sleep. a Manhattan plot of sleep duration (n= 446,118) and b
Miami plot of short (cases n= 106,192/305,742) and long (cases n= 34,184/305,742) sleep. Plots show the −log10P values (y-axis) for all genotyped and
imputed single-nucleotide polymorphisms (SNPs) passing quality control in each genome-wide association study (GWAS), plotted by chromosome (x-
axis). Blue peaks represent genome-wide signiﬁcant loci. Horizontal red line denotes genome-wide signiﬁcance (P= 5 × 10−8)
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Association of sleep duration loci with objective sleep. Given
the limitations of self-reported sleep duration23,24, and in order to
explore underlying physiologic mechanisms, in secondary ana-
lyses, we tested the 78 lead variants for association with 8
accelerometer-derived sleep estimates in a subgroup who had
completed up to 7 days of wrist-worn accelerometry (n= 85,499;
Supplementary Table 8)25. The lead PAX8 genetic variant was
associated with 2.68 min (0.29) longer sleep duration (compared
to 2.44 min (0.16) by self-report), 0.21% (0.04%) greater sleep
efﬁciency, and 0.94 min (0.23) greater daytime inactivity duration
per minor A allele (P < 0.00064; Supplementary Data 8). The 5%
of participants carrying the most sleep duration-increasing alleles
were estimated to have 9.7 min (95% CI: 7.5–11.8) accelerometer
measured longer sleep duration compared to the 5% carrying the
fewest. The 78 SNP GRS associated with longer accelerometer-
derived sleep duration, longer duration of daytime inactivity,
greater sleep efﬁciency, and larger number of sleep bouts, but not
with day-to-day variability in sleep duration or estimates of sleep
timing (Table 1). A GRS of 27 short sleep variants was associated
with shorter accelerometer-derived sleep duration, lower sleep
efﬁciency, and fewer sleep bouts, whereas a GRS of 8 long sleep
variants associated with longer accelerometer-derived sleep
duration, higher sleep efﬁciency, and longer daytime inactivity
(Table 1, Supplementary Data 9).
Functional annotation for identiﬁed loci. The sleep duration
association signals encompass >200 candidate causal genes
determined by SNPsea26 through assessing linkage disequilibrium
(LD) intervals of each identiﬁed loci, deﬁned by the furthest SNPs
in a 1Mb window with r2 > 0.05, and a summary of reported
gene–phenotype annotations is shown in Supplementary Data 10.
Compelling candidates include genes in the dopaminergic
(DRD2, SLC6A3), MAPK/ERK (mitogen-activated protein kinase/
extracellular signal-regulated kinase) signaling (ERBB4, VRK2,
KSR2), orexin receptor (HCRTR2), and GABA (GABRR1) sig-
naling systems4,27. Further, studies of sleep regulation in animal
models prioritize several candidates (GABRR1, GNAO1,
HCRTR2, NOVA1, PITX3, SLC6A3, DRD2, and VAMP2 for sleep
duration; PDE4B and SEMA3F for short sleep; PDE4D for long
sleep). Circadian genes within associated loci include PER3,
BTRC, and the previously implicated PER128, which may act
through glucocorticoid stress-related pathways to inﬂuence sleep
duration. Association signals at 4 loci directly overlapped with
other GWAS signals (r2 > 0.8 in 1KG CEU; from the National
Human Genome Research Institute (NHGRI)), with the shorter
sleep allele associated with higher BMI (FTO), increased risk of
Crohn’s disease (NFKB1, SLC39A8, BANK1 region), febrile sei-
zures and generalized epilepsy (SCN1A), and cardiometabolic risk
(FADS1/2 gene cluster), and decreased risk of interstitial lung
disease (MAPT/KANSL). Fine-mapping using credible set analysis
in PICS29 highlighted 52 variants (Supplementary Data 11, 12).
Partitioning of heritability by functional annotations identiﬁed
excess heritability across genomic regions conserved in mammals,
consistent with earlier ﬁndings18, and additionally in regions with
active promoters and enhancer chromatin marks (Supplementary
Data 13).
Gene- and pathway-based analysis. Gene-based tests identiﬁed
235, 54, and 20 genes associated with sleep duration, short sleep,
and long sleep, respectively (P≤ 2.29 × 10−6; Supplementary
Table 1 A risk score of genetic variants for self-reported sleep duration (78 SNPs), self-reported short (27 SNPs) or long (8
SNPs) sleep duration associates with self-reported sleep duration in the CHARGE (adult) consortium (n= 47,180), self-reported
sleep duration in the EAGLE (childhood/adolescent) consortium (n= 10,554), and activity-monitor-based measures of sleep
fragmentation, timing, and duration from 7-day accelerometry in the UK Biobank (n= 85,499)
Sleep duration GRS Short sleep GRS Long sleep GRS
Trait Beta or OR* (95% CI)
per effect allele
P value Beta or OR* (95% CI) per
effect allele
P value Beta or OR* (95% CI)
per effect allele
P value
CHARGE Study (n= 47,180); self-reported
sleep duration (min)a
0.66 (0.54 to 0.78) 1.23 × 10−25
EAGLE Study (n= 10,554); self-reported
sleep duration (min)b
0.16 (0.02 to 0.30) 2.80 × 10−2
UK Biobank 7-day accelerometry
(n= 85,499) sleep duration estimates
Sleep duration (min) 0.47 (0.40 to 0.53) 1.93 × 10−44 −0.43 (−0.56 to −0.31) 1.21 × 10−11 2.12 (1.65 to 2.59) 1.08 × 10−18
Short sleep duration (n= 13,760 cases,
66,110 controls)
0.98 (0.98 to 0.99)* 4.00 × 10−19 1.02 (1.01 to 1.02)* 4.91 × 10−6 0.94 (0.92 to 0.97)* 1.10 × 10−5
Long sleep duration (n= 5629 cases,
66,110 controls)
1.01 (1.01 to 1.02)* 3.78 × 10−9 0.99 (0.98 to 1.00)* 0.11 1.10 (1.07 to 1.14)* 1.29 × 10−8
Daytime inactivity duration (min) 0.08 (0.03 to 0.13) 2.74 × 10−3 0.01 (−0.09 to 0.11) 0.89 0.65 (0.28 to 1.02) 6.49 × 10−4
Sleep duration standard deviation (min) −0.02 (−0.07 to 0.02) 0.34 0.05 (−0.04 to 0.14) 0.26 −0.07 (−0.40 to 0.27) 0.69
Sleep fragmentation estimates
Sleep efﬁciency % 0.05 (0.04 to 0.06) 8.38 × 10−23 −0.05 (−0.07 to −0.04) 4.79 × 10−9 0.15 (0.08 to 0.22) 1.56 × 10−5
Number of sleep bouts (n) 0.02 (0.01 to 0.02) 1.59 × 10−10 −0.01 (−0.02 to 0.00) 2.42 × 10−3 0.02 (−0.01 to 0.05) 0.24
Sleep timing estimates
Midpoint of 5 h daily period of minimum
activity (L5 timing) (minutes)
−0.05 (−0.13 to 0.03) 0.23 0.07 (−0.09 to 0.22) 0.41 0.39 (−0.20 to 0.97) 0.20
Midpoint of 10 h daily period of maximum
activity (M10 timing) (minutes)
0.03 (−0.06 to 0.12) 0.51 −0.05 (−0.23 to 0.12) 0.55 0.65 (−0.02 to 1.32) 6.00 × 10−2
Sleep midpoint (min) −0.03 (−0.07 to 0.01) 0.20 0.01 (−0.07 to 0.08) 0.88 0.05 (−0.24 to 0.34) 0.74
Genetic risk scores for sleep duration, short sleep and long sleep were tested using the weighted genetic risk score calculated by summing the products of the sleep trait risk allele count for all 78, 27, or
8 genome-wide signiﬁcant SNPs multiplied by the scaled effect from the primary genome-wide association study (GWAS) using the GTX package in R. Effect estimates (beta or OR) are reported per
additional effect allele for sleep duration, short sleep, or long sleep. Signiﬁcant GRS associations (P < 0.05) are shown in bold.
SNP single-nucleotide polymorphism, CI conﬁdence interval, GRS genetic risk score, OR odds ratio, CHARGE Cohorts for Heart and Aging Research in Genomic Epidemiology, EAGLE EArly Genetics and
Lifecourse Epidemiology
aSelf-reported and varied by cohorts, typically: “How many hours of sleep do you usually get at night (or your main sleep period)?”
bIn all cohorts, except in GLAKU, child sleep duration was assessed by a single, parent-rated, open question, “How many hours does your child sleep per day including naps?” In GLAKU, parents were
asked about the usual bed and rise times during school days, from which the total sleep duration could be estimated
*indicates OR (95% CI)
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Data 14, 15). Pathway analyses of these genes using MAGMA30
and Pascal31 indicated enrichment of pathways including stria-
tum and subpallium development, mechanosensory response,
dopamine binding, catecholamine production, and long-term
depression (Fig. 2a, b, Supplementary Table 9, 10). In agreement
with the FADS1/2 signal, we also observe enrichment in genes
related to unsaturated fatty acid metabolism. A custom pathway
analysis in Pascal indicated enrichment of association in a gene-
set of synaptic sleep-need-index phosphoproteins (SNIPPs),
which have recently been demonstrated to be differentially
phosphorylated based on sleep need in mouse models6 (Supple-
mentary Table 11; Pemp= 1.44 × 10−4). Of these, associations at
SCN1A and PDE4B are genome-wide signiﬁcant.
Tissue enrichment analyses of gene expression from Genotype-
Tissue Expression (GTEx) tissues identiﬁed enrichment of
associated genes in several brain regions including the cerebellum,
a region of emerging importance in sleep/wake regulation32,
frontal cortex, anterior cingulated cortex, nucleus accumbens,
caudate nucleus, hippocampus, hypothalamus, putamen, and
amygdala (Fig. 2c, Supplementary Table 12). Enrichment was also
observed in the pituitary gland. Single cell enrichment analyses in
FUMA using a recently described Tabula Muris33 dataset showed
enrichment in brain neurons and pancreatic alpha cells (Supple-
mentary Data 16). Integration of gene expression data with GWAS
using transcriptome-wide association analyses in 11 tissues34
identiﬁed 38 genes for which sleep duration SNPs inﬂuence gene
expression in the tissues of interest (Supplementary Data 17).
Several lead SNPs were associated with one or more of 3144
human brain structure and function traits assessed in the UK
Biobank (P < 2.8 × 10−7, n= 9,707; Oxford Brain Imaging
Genetics Server;35 Supplementary Figure 6). These include
associations between the PAX8 locus with resting-state functional
magnetic resonance imaging networks (Supplementary Figure 6a,
6h, 6m), rs13109404 (BANK1; Supplementary Figure 6b) and
bilateral putamen and striatum volume, possibly relating to
functional ﬁndings on reward processing after experimental sleep
deprivation36, and rs330088 (PPP1R3B region; Supplementary
Figure 6c) and temporal cortex morphometry, which may relate
to recent ﬁndings showing extreme sleep durations predict
subsequent frontotemporal gray matter atrophy37.
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Genetic correlation and Mendelian randomization. Genome-
wide genetic correlations using LD score regression analyses38
indicated shared links between sleep duration and eight cognitive,
psychiatric, and physical disease traits (Fig. 3, Supplementary
Data 18). We observed modest positive genetic correlations
between sleep duration and schizophrenia, bipolar disorder, and
age at menarche, and a negative correlation with insomnia that
persisted even upon excluding participants with psychiatric
disorders, indicating that genetic relationships are not driven by
the presence of co-morbid conditions. In addition, both short and
long sleep showed positive genetic correlations with depressive
symptoms, waist circumference, and waist-to-hip ratio, and
negative correlations with years of schooling. For short sleep,
genetic correlations were also observed with insomnia, neuroti-
cism, and smoking, and for long sleep, positive correlations were
evident with schizophrenia, body fat, type 2 diabetes, and cor-
onary artery disease.
Mendelian randomization (MR) analyses to test for causal links
between sleep duration and genetically correlated traits suggested
longer sleep duration is causal for increased risk of schizophrenia
(two-sample MR: inverse variance weighted: 0.0088 (0.003) log
odds ratio per min, P= 3.70 × 10−3; weighted median: 0.008
(0.003) log odds ratio per min, P= 3.95 × 10−3) (Fig. 4,
Supplementary Table 13). These data suggest that a 1 h longer
sleep duration leads to a 69.6% increase in the risk for
schizophrenia. In leave-one-out sensitivity analyses, MR results
remained robust and consistent (all P < 6.86 × 10−3; Supplemen-
tary Data 19). Sensitivity MR analyses limited to signals from
GWAS adjusting for confounders (BMI, insomnia, or other
lifestyle traits) and using corresponding effect estimates remained
signiﬁcant (Supplementary Table 14). In addition, MR remained
signiﬁcant when restricted to the 56 signals that retained GWAS
signiﬁcance in meta-analysis (Supplementary Table 14). Con-
versely, MR also indicated that risk of schizophrenia is causal for
longer sleep duration (inverse variance weighted: 0.025 min
(0.007) per log odds ratio, P= 6.05 × 10−4; two-sample MR:
weighted median: 0.026 min (0.006) per log odds ratio, P=
3.36 × 10−5) (Fig. 4, Supplementary Table 14). These data suggest
a 1.04 h longer sleep duration per doubling in risk of
schizophrenia. No other causal links were identiﬁed in two-
sample MR. Furthermore, using two-sample MR with data from
the GIANT consortium39 (n= 339,224) and DIAGRAM con-
sortium40 (n= 26,488 cases and n= 83,964 controls), we found
no evidence of causal effects of altered sleep duration with BMI
and type 2 diabetes (Supplementary Table 13, Supplementary
Figure 7).
Discussion
This study expands our understanding of the genetic architecture
of self-reported sleep duration, estimating SNP-based heritability
at 9.8%, consistent with earlier reports41. We identiﬁed 76 inde-
pendent loci beyond the two previously known loci (PAX8 and
VRK214,17,18). The largest effect remains at the PAX8 locus (2.44
min per allele), consistent with previous reports14,17,18. Whereas
individual signals exerted more modest effects on average (~1.04
min per allele), the aggregate effect of risk alleles could exceed 20
min, which is comparable to other well-recognized factors
inﬂuencing sleep duration, such as gender42. Our GWAS ﬁndings
were largely consistent upon adjustment for known risk factors,
including BMI; however, attenuated effects were seen for some
loci with adjustment for insomnia, reﬂecting some overlap
between these sleep characteristics.
In separate GWAS for short and long sleep duration, 13
additional independent variants were identiﬁed, and only the
PAX8 locus was shared across all 3 GWASs. Our distinct ﬁndings
for short and long sleep suggest the possibility of some distinct
underlying biological mechanisms. As all three sleep traits were
correlated, however, we did not account for multiple testing as
have been done in previous GWAS of multiple correlated traits18.
Future larger studies will be necessary to test if these loci reﬂect
partially distinct genetic effects on short or long sleep, or reﬂect
differences in statistical power in these dichotomized analyses.
The CHARGE consortium (adults) and EAGLE consortium
(children/adolescents) sleep duration GWAS studies represent the
largest independent available studies for replication, but are
considerably smaller than the UK Biobank discovery cohort
which limits opportunities for adequate replication43. Indeed, we
had limited power to replicate individual SNPs in the two repli-
cation cohorts: the CHARGE consortium study with ~1/10th the
sample size of the UK Biobank provided <12.5% power for all
SNPs that did not individually replicate, and the EAGLE con-
sortium study with ~1/40th the sample size of the UK Biobank
provided power <70% for all SNPs that did not individually
replicate. Despite these limitations, 52 loci remained signiﬁcant
after meta-analysis of both adult studies and 56 loci remained
signiﬁcant after meta-analysis of all three studies, a substantial
advance over knowledge from prior studies. Future replication is
necessary when appropriate resources become available, such as
the US Department of Veterans Affairs Million Veteran Program
and the All of Us Research program.
Furthermore, we validated effects of the combined sleep
duration GRS in both adults and children/adolescents, further
supporting our ﬁndings. Consistency between ﬁndings from the
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UK Biobank GWAS and sleep duration in independent studies
despite differences in demographics and sleep duration ascer-
tainment, two important extraneous factors that may inﬂuence
self-report44, reﬂect the generalizability of our signals. However,
smaller effect estimates of the GRS in children/adolescents
compared to adults supports previous studies that suggest the
genetic architecture of sleep duration might differ between chil-
dren and adults19. Furthermore, our ﬁnding of no signiﬁcant
overall genetic correlation between the GWAS of adults and
children/adolescents sleep duration, as reported previously19,
supports changes in sleep patterns throughout the lifespan45–47,
and larger GWAS of sleep duration in children/adolescents are
needed.
Despite limitations of biases and imprecision in self-report, we
observed largely consistent effects of our 78 signals with
accelerometer-estimated sleep duration in a large subsample of
85,499 participants from the UK Biobank with up to 7 days of
wrist-worn accelerometer. Self-report, actigraphy, and poly-
somnography estimated sleep duration provide both unique and
overlapping information, have different sources of measurement
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error, and may reﬂect different neurophysiological and psycho-
logical aspects23,24,44. Association of the sleep duration GRS with
increased sleep efﬁciency, longer duration of daytime inactivity,
but a larger number of sleep bouts, suggests that sleep duration
genetic loci might impact other correlated parameters such as
sleep latency, sleep fragmentation, and early awakening. There-
fore, this secondary analysis allows us to begin exploring phy-
siologic mechanisms underlying these associations. However,
considering that the UK Biobank subsample with accelerometer
data overlap with the discovery GWAS sample, these results
should be interpreted with caution and further validation in an
independent dataset is necessary. Furthermore, our study cannot
resolve if a longer sleep GRS always reﬂects improved, higher
quality sleep because of increased sleep efﬁciency, or may include
qualitatively poorer, longer sleep or greater sleep need, given
association with a larger number of sleep bouts and increased
daytime napping. Thus, further investigation of the role of these
loci in electroencephalography-derived physiological correlates of
sleep architecture and sleep homeostasis from polysomnography
and follow-up in cellular and animal models will help to dissect
functional mechanisms.
We found compelling evidence of association near genes
implicated with sleep traits in animal models, conﬁrming that
sleep–wake regulation is a highly conserved process with
mechanisms shared between humans and model organisms. In
agreement with the FADS1/2 signal, we also observe an enrich-
ment in genes related to unsaturated fatty acid metabolism,
supporting experimental and observational evidence linking
polyunsaturated fatty acids with sleep and related diseases,
including neuropsychiatric disorders and depression48–50. We
demonstrate enrichment in sleep duration GWAS signals within/
near 80 genes identiﬁed as SNIPPs in mouse models6, high-
lighting the potential importance of synaptic phosphorylation in
sleep homeostasis in humans. A genetic variant, rs9382445, near
the orexin receptor HCRTR2 previously implicated for chron-
otype17 associated signiﬁcantly with sleep duration and retained
signiﬁcance and consistent effect estimates upon adjustment for
diurnal preference.
Lastly, we extended the comparative analysis of the genetic
architecture of sleep duration with other traits and found shared
links between continuous sleep duration and cognitive, psychia-
tric, and disease traits, as well as u-shaped genetic correlations
between short and long sleep duration and key lifestyle and dis-
ease traits including adiposity traits, years of schooling, and
depressive symptoms. In bidirectional two-sample MR analyses,
we observed causal links between longer sleep duration and
increased risk of schizophrenia, consistent with previous
ﬁndings18,51, and conversely, causal links between schizophrenia
and longer sleep duration. Associations remained robust in sen-
sitivity analyses and the bidirectional causal link may suggest
pleiotropy. Furthermore, MR effects may be biased due to collider
bias as individuals with a genetic liability to neuropsychiatric
diseases are underrepresented in studies such as the UK Biobank
compared to the general population, while some independent
protective factors for these conditions, including favorable sleep
patterns, may be over-represented52,53. No other causal links were
identiﬁed. Considering the non-speciﬁc and partially overlapping
signals between the sleep duration and short/long sleep GWAS,
we limited our MR analyses to sleep duration, and future MR
should be carried out for short/long sleep duration separately.
Follow-up MR analyses are warranted to verify null results
identiﬁed in the one-sample insomnia MR, as well as other out-
comes beyond those investigated.
In summary, our GWAS constitutes a large increase in asso-
ciated loci for sleep duration that implicate multiple biological
pathways and causal links to disease. This work and follow-up
studies will advance understanding of the molecular processes
underlying sleep regulation and have the potential to identify new
avenues of treatment for sleep and related disorders.
Methods
Population and study design. Study participants were from the UK Biobank
study, described in detail elsewhere54. In brief, the UK Biobank is a prospective
study of >500,000 people living in the United Kingdom. All people in the National
Health Service registry who were aged 40–69 years and living <25 miles from a
study center were invited to participate between 2006 and 2010. In total, 503,325
participants were recruited from over 9.2 million invitations. Extensive phenotypic
data were self-reported upon baseline assessment by participants using touchscreen
tests and questionnaires and at nurse-led interviews. Anthropometric assessments
were also conducted and health records were obtained from secondary care data
from linked Hospital episode statistics (HES) obtained up until 04/2017. For the
current analysis, 24,533 individuals of non-white ethnicity (as deﬁned in geno-
typing and quality control) were excluded to avoid confounding effects. The UK
Biobank study was approved by the National Health Service National Research
Ethics Service (ref. 11/NW/0382), and all participants provided written informed
consent to participate in the UK Biobank study.
Sleep duration and covariate measures. Study participants (n ~ 500,000) self-
reported sleep duration at baseline assessment. Participants were asked: About how
many hours sleep do you get in every 24 h? (please include naps), with responses in
hour increments. Sleep duration was treated as a continuous variable and also
categorized as either short (6 h or less), normal (7 or 8 h), or long (9 h or more)
sleep duration. Extreme responses of less than 3 h or more than 18 h were exclu-
ded17 and Do not know or Prefer not to answer responses were set to missing.
Participants who self-reported any sleep medication (see Supplementary Method 1)
were excluded. Furthermore, participants who self-reported any shift work or night
shift work or those with prevalent chronic disease (i.e., breast, prostate, bowel or
lung cancer, heart disease, or stroke) or psychiatric disorders (see Supplementary
Method 2) were later additionally excluded in a secondary GWAS.
Participants further self-reported age, sex, caffeine intake (self-reported cups of
tea per day and cups of coffee per day), daytime napping (Do you have a nap
during the day?), smoking status, alcohol intake frequency (never, once/week, 2–3
times/week, 4–6 times/week, daily), chronotype (Do you consider yourself to be …,
with the following response options: Deﬁnitely a ‘morning’ person, More a
‘morning’ than ‘evening’ person, More an ‘evening’ than a ‘morning’ person, and
Deﬁnitely an ‘evening’ person), menopause status, and employment status during
assessment. Socio-economic status was represented by the Townsend deprivation
index based on national census data immediately preceding participation in the UK
Biobank. Weight and height were measured and BMI was calculated as weight (kg)/
height2(m2). Cases of sleep apnea were determined from self-report during nurse-
led interviews or health records using International Classiﬁcation of Diseases
(ICD)-10 codes for sleep apnea (G47.3). Cases of insomnia were determined from
self-report to the question, Do you have trouble falling asleep at night or do you
wake up in the middle of the night? with responses never/rarely, sometimes, usually,
prefer not to answer. Participants who responded usually were set as insomnia
cases, and remaining participants were set as controls. Missing covariates were
imputed using sex-speciﬁc median values for continuous variables (i.e., BMI,
caffeine intake, alcohol intake, and Townsend index), or using a missing indicator
approach for categorical variables (i.e., napping, smoking, menopause,
employment, and chronotype).
Activity-monitor-derived measures of sleep. Actigraphy devices (Axivity AX3)
were worn 2.8–9.7 years after study baseline by 103,711 individuals from the UK
Biobank for up to 7 days55. Of these 103,711 individuals, we excluded 11,067
individuals based on accelerometer data quality. Samples were excluded if they
satisﬁed at least one of the following conditions (see also http://biobank.ctsu.ox.ac.
uk/crystal/label.cgi?id=1008): a non-zero or missing value in data ﬁeld 90002 (Data
problem indicator), good wear time ﬂag (ﬁeld 90015) set to 0 (No), good cali-
bration ﬂag (ﬁeld 90016) set to 0 (No), calibrated on own data ﬂag (ﬁeld 90017) set
to 0 (No), or overall wear duration (ﬁeld 90051) less than 5 days. Additionally,
samples with extreme values of mean sleep duration (<3 h or >12 h) or mean
number of sleep periods (<5 or >30) were excluded. After non-white ethnicity
exclusions, 85,502 samples remained. Sleep measures were derived by processing
raw accelerometer data (.cwa). First, we converted .cwa ﬁles available from the UK
Biobank to .wav ﬁles using Omconvert (https://github.com/digitalinteraction/
openmovement/tree/master/Software/AX3/omconvert) for signal calibration to
gravitational acceleration55,56 and interpolation55. The .wav ﬁles were processed
with the R package GGIR to infer activity-monitor wear time57, and extract the z-
angle across 5-s epoch time-series data for subsequent use in estimating the sleep
period time window (SPT-window)25 and sleep episodes within it58.
The SPT-window was estimated using an algorithm25 implemented in the
GGIR R package and validated using polysomnography (PSG) in an external
cohort consisting of 28 adult sleep clinic patients and 22 healthy good sleepers.
Brieﬂy, for each individual, median values of the absolute change in z-angle
(representing the dorsal–ventral direction when the wrist is in the anatomical
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position) across 5-min rolling windows were calculated across a 24 h period,
chosen to make the algorithm insensitive to activity-monitor orientation. The 10th
percentile was incorporated into the threshold distinguishing movement from non-
movement. Bouts of inactivity lasting ≥30 min are recorded as inactivity bouts.
Inactivity bouts that are <60 min apart are combined to form inactivity blocks. The
start and end of longest block deﬁnes the start and end of the SPT-window25.
Sleep duration: Sleep episodes within the SPT-window were deﬁned as periods
of at least 5 min with no change larger than 5° associated with the z-axis of the
accelerometer58. The summed duration of all sleep episodes was used as indicator
of sleep duration.
Sleep efﬁciency: This was calculated as sleep duration (deﬁned above) divided
by the time elapsed between the start of the ﬁrst inactivity bout and the end of the
last inactivity bout (which equals the SPT-window duration).
Number of sleep bouts within the SPT-window: This is deﬁned as the number
of sleep bouts separated by last least 5 min of wakefulness within the SPT-window.
The least-active 5 h hours (L5) and the most-active 10 h (M10) of each day were
deﬁned using a 5 h and 10 h daily period of minimum and maximum activity,
respectively. These periods were estimated using a rolling average of the
respectively time window. L5 was deﬁned as the number of hours elapsed from the
previous midnight, whereas M10 was deﬁned as the number of hours elapsed from
the previous midday.
Sleep midpoint: Sleep midpoint was calculated for each sleep period as the
midpoint between the start of the ﬁrst detected sleep episode and the end of the last
sleep episode used to deﬁne the overall SPT-window (above). This variable is
represented as the number of hours from the previous midnight, e.g., 2am= 26.
Daytime inactivity duration: Daytime inactivity duration is the total daily
duration of estimated bouts of inactivity that fall outside of the SPT-window. A
minimum of 16 wear-hours was required for each night to be included. For non-
wear data, the sleep phenotypes were imputed. Brieﬂy, a minimum of 16 wear-
hours was required for each night to be included. For each 15-min block that was
classiﬁed as non-wear, data were replaced by the average of blocks at the same time
periods from the other days in each individual record57. All activity-monitor
phenotypes were adjusted for age at accelerometer wear, sex, season of wear, release
(categorical; UK BiLeVe, UK Biobank Axiom interim, release UK Biobank Axiom
full release), and number of valid recorded nights (or days for M10) when
performing the association test in BOLT-LMM. Genetic risk scores for sleep
duration, short sleep, and long sleep were tested using the weighted genetic risk
score calculated by summing the products of the sleep trait risk allele count for all
78, 27, or 8 genome-wide signiﬁcant SNPs multiplied by the scaled effect from the
primary GWAS using the GTX package in R.
Genotyping and quality control. Phenotype data are available for 502,631 subjects
in the UK Biobank. Genotyping was performed by the UK Biobank, and geno-
typing, quality control, and imputation procedures are described in detail here59. In
brief, the following was conducted by the UK Biobank. Blood, saliva, and urine was
collected from participants, and DNA was extracted from the buffy coat samples.
Participant DNA was genotyped on two arrays, UK BiLEVE and UK Biobank
Axiom with >95% common content and genotypes for ~800,000 autosomal SNPs
were imputed to two reference panels. Genotypes were called using Affymetrix
Power Tools software. Sample and SNPs for quality control were selected from a set
of 489,212 samples across 812,428 unique markers. Sample quality control (QC)
was conducted using 605,876 high-quality autosomal markers. Samples were
removed for high missingness or heterozygosity (968 samples) and sex chromo-
some abnormalities (652 samples). Genotypes for 488,377 samples passed sample
QC (~99.9% of total samples). Marker-based QC measures were tested in the
European ancestry subset (n= 463,844), which was identiﬁed based on principal
components of ancestry. SNPs were tested for batch effects (197 SNPs/batch), plate
effects (284 SNPs/batch), Hardy–Weinberg equilibrium (572 SNPs/batch), sex
effects (45 SNPs/batch), array effects (5417 SNPs), and discordance across control
replicates (622 on UK BiLEVE Axiom array and 632 UK Biobank Axiom array) (p
value < 10−12 or <95% for all tests). For each batch (106 batches total) markers that
failed at least one test were set to missing. Before imputation, 805,426 SNPs pass
QC in at least one batch (>99% of the array content). Population structure was
captured by principal component analysis on the samples using a subset of high-
quality (missingness < 1.5%), high-frequency SNPs (>2.5%) (~100,000 SNPs) and
identiﬁed the subsample of white British descent. In addition to the calculated
population structure by the UK Biobank, we locally further clustered subjects into
four ancestry clusters using K-means clustering on the principal components,
identifying 453,964 subjects of European ancestry. The UK Biobank centrally
further imputed autosomal SNPs to UK10K haplotype, 1000 Genomes Phase 3, and
Haplotype Reference Consortium (HRC) with the current analysis using only those
SNPs imputed to the HRC reference panel. Autosomal SNPs were pre-phased using
SHAPEIT3 and imputed using IMPUTE4. In total, ~96 million SNPs were
imputed. Related individuals were identiﬁed by estimating kinship coefﬁcients for
all pairs of samples, using only markers weakly informative of ancestral back-
ground. In total, there are 107,162 related pairs comprising 147,731 individuals
related to at least one other participants in the UK Biobank.
Genome-wide association analysis. Genetic association analysis was performed
in related subjects of European ancestry (n= 446,118) using BOLT-LMM60 linear
mixed models and an additive genetic model adjusted for age, sex, 10 principal
components of ancestry, genotyping array, and genetic correlation matrix [jl2] with
a maximum per SNP missingness of 10% and per sample missingness of 40%. We
used a genome-wide signiﬁcance threshold of 5 × 10−8 for each GWAS. Odds ratio
(OR; 95% CI) estimates for short/long sleep are from adjusted PLINK61 logistic
regression analyses where genetic association analysis was also performed in
unrelated subjects of white British ancestry (n= 326,224) using PLINK logistic
regression and an additive genetic model adjusted for age, sex, 10 PCs, and gen-
otyping array to determine SNP effects on sleep traits. We used a hard-call gen-
otype threshold of 0.1, SNP imputation quality threshold of 0.80, and a minor allele
frequency (MAF) threshold of 0.001. Genetic association analysis for the X chro-
mosome was performed using the genotyped markers on the X chromosome with
the additional –sex ﬂag in PLINK. Similarly, sex-speciﬁc GWASs were also per-
formed using BOLT-LMM60 linear mixed models. Trait heritability was calculated
as the proportion of trait variance due to additive genetic factors measured in this
study using BOLT-REML60, to leverage the power of raw genotype data together
with low-frequency variants (MAF ≥ 0.001). Lambda inﬂation (λ) values were
calculated using GenABEL in R, and estimated values were consistent with those
estimated for other highly polygenic complex traits. Additional independent risk
loci were identiﬁed using the approximate conditional and joint association
method implemented in GCTA (GCTA-COJO)62.
Sensitivity analyses of top signals. Follow-up analyses on genome-wide sig-
niﬁcant loci in the primary analyses included covariate sensitivity analyses
adjusting for BMI, insomnia (continuous only), chronotype (continuous only), or
caffeine intake adjustments individually, or a combined adjustment for lifestyle and
clinical traits, including day naps, Townsend index, smoking, alcohol intake,
menopause status, employment status, and sleep apnea in addition to baseline
adjustments for age, sex, 10 principal components of ancestry, and genotyping
array. Sensitivity analyses were performed using BOLT-LMM60 linear mixed
models using the same input set of SNPS (i.e., hard-call genotypes) as for the main
GWAS, and OR (95% CI) estimates for short/long sleep are from adjusted PLINK61
logistic regression analyses in unrelated subjects of white British ancestry.
Replication and meta-analyses of sleep duration loci. Using publicly available
databases, we conducted a lookup of lead self-reported sleep duration signals in
self-reported sleep duration GWAS results from adult (CHARGE; n= 47,180)
and childhood/adolescent (EAGLE; n= 10,554). If lead signal was unavailable, a
proxy SNP was used instead. As different imputation panels were used compared
to the UK Biobank, 8 of the 78 SNPs and 1 of the 78 SNPs were not covered in
the CHARGE consortium and EAGLE consortium, respectively. In addition, we
combined self-reported sleep duration GWAS results from adult (CHARGE) and
childhood/adolescent (EAGLE) with the UK Biobank (primary model) in ﬁxed-
effects meta-analyses using the inverse variance weighted method in METAL63.
Meta-analyses were conducted ﬁrst separately (UK Biobank+ CHARGE (n=
3,044,490 variants) or UK Biobank+ EAGLE (n= 7,147,509 variants)), then
combined (UK Biobank+ CHARGE+ EAGLE; n= 2,545,157 variants). A
genetic risk score (GRS) for sleep duration was tested using the weighted
GRS calculated by summing the products of the sleep duration risk allele count
for as many available SNPs of the 78 genome-wide signiﬁcant SNPs in each
study (70 for CHARGE, 77 for EAGLE) multiplied by the scaled effect from the
primary GWAS using the GTX package in R64.
Gene, pathway, and tissue enrichment analyses. Genes overlapping the LD
interval of the identiﬁed loci, deﬁned by the furthest SNPs in a 1Mb window with
r2 > 0.05, were identiﬁed by SNPsea26. Gene-based analysis was performed using
Pascal31. Pascal gene-set enrichment analysis uses 1077 pathways from KEGG,
REACTOME, BIOCARTA databases, and a signiﬁcance threshold was set after
Bonferroni correction accounting for 1077 pathways tested (P < 0.05/1,077).
Pathway analysis was also conducted using MAGMA30 gene-set analysis in
FUMA65, which uses the full distribution of SNP P values and is performed for
curated gene sets and Gene Ontology (GO) terms obtained from MsigDB (total of
10,891 pathways). A signiﬁcance threshold was set after Bonferroni correction
accounting for all pathways tested (P < 0.05/10,891). Using Pascal, we created a
custom pathway of the SNIPP genes6 using human orthologs identiﬁed in DAVID
(Database for Annotation, Visualization and Integrated Discovery; 79 out of 80
identiﬁed SNIPPs). We then veriﬁed enrichment of the pathway in our sleep
duration GWAS (continuous, short, and long sleep). Tissue enrichment analysis
was conducted using FUMA65 for 53 tissue types, and a signiﬁcance threshold was
set following Bonferroni correction accounting for all tested tissues (P < 0.05/53).
Single cell enrichment analysis was conducted in FUMA65 utilizing the Tabula
Muris33 dataset, and a signiﬁcance threshold was set following Bonferroni cor-
rection accounting for all tested cell types (P < 0.05/115). Integration of gene
expression data with GWAS using transcriptome-wide association analyses in 11
tissues34 identiﬁed 38 genes for which sleep duration SNPs inﬂuence gene
expression in the tissues of interest (Supplementary Table 28). Integrative
transcriptome-wide association analyses with GWAS were performed using the
FUSION TWAS package34 with weights generated from gene expression in 9 brain
regions and 2 tissues from the GTEx consortium (v6). Tissues for TWAS testing
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were selected from the FUMA tissue enrichment analyses and here we present
signiﬁcant results that survive Bonferroni correction for the number of genes tested
per tissue and for all 11 tissues.
Genetic correlation analyses. Post-GWAS genome-wide genetic correlation
analysis of LD Score Regression (LDSC)66–68 using LDHub was conducted using all
UK Biobank SNPs also found in HapMap3 and included publicly available data
from 224 published genome-wide association studies, with a signiﬁcance threshold
after Bonferroni correction for all tests performed (P < 0.05/224 tests). LDSC
estimates genetic correlation between two traits from summary statistics (ranging
from −1 to 1) using the fact that the GWAS effect-size estimate for each SNP
incorporates effects of all SNPs in LD with that SNP, SNPs with high LD have
higher X2 statistics than SNPs with low LD, and a similar relationship is observed
when single study test statistics are replaced with the product of z-scores from two
studies of traits with some correlation. Furthermore, genetic correlation is possible
between case/control studies and quantitative traits, as well as within these trait
types. We performed partitioning of heritability using the 8 pre-computed cell-type
regions, and 25 pre-computed functional annotations available through LDSC,
which were curated from large-scale robust datasets66. Enrichment both in the
functional regions and in an expanded region (+500 bp) around each functional
class was calculated in order to prevent the estimates from being biased upward by
enrichment in nearby regions. The multiple testing threshold for the partitioning of
heritability was determined using the conservative Bonferroni correction (P < 0.05/
25 classes). Summary GWAS statistics will be made available at the UK Biobank
web portal.
Mendelian randomization analyses. MR analysis was carried out using the R
package MR-Base69 (available: github.com/MRCIEU/TwoSampleMR), using the
inverse variance weighted approach as our main analysis method70, and MR-
Egger71 and weighted median estimation72 as sensitivity analyses. MR results
may be biased by horizontal pleiotropy—i.e., where the genetic variants that are
robustly related to the exposure of interest (here sleep duration) independently
inﬂuence levels of a causal risk factor for the outcome. Inverse variance weighted
(IVW) assumes that there is either no horizontal pleiotropy, or that across all
SNPs, horizontal pleiotropy is (i) uncorrelated with SNP-risk factor associations
and (ii) has an average value of zero. MR-Egger assumes (i) but relaxes (ii) by
explicitly estimating the non-zero mean pleiotropy, and adjusting the causal
estimate accordingly. Estimation of the pleiotropy parameter means that the
MR-Egger estimate is generally far less precise than the IVW estimate. The
weighted median approach is valid if less than 50% of the weight is pleiotropic
(i.e., no single SNP that contributes 50% of the weight or a number of SNPs that
together contribute 50% should be invalid because of horizontal pleiotropy).
Given these different assumptions, if all three methods are broadly consistent,
this strengthens our causal inference. For all our MR analyses, except insomnia,
we used two-sample MR, in which for all 78 GWAS hits identiﬁed in this study
for sleep duration, we looked for the per allele difference in odds (binary out-
comes) or means (continuous) with outcomes from summary publicly available
data in the MR-Base platform. Results are therefore a measure of ‘longer sleep
duration’ and sample 1 is UK Biobank (our GWAS) and sample 2 a number of
different GWAS consortia covering the outcomes we explored. For interpreta-
tion purposes, inverse variance weighted MR causal effect estimates were con-
verted in OR per hour by multiplying log ORs by 60 in order to represent the OR
per hour, and then exponentiating. For signiﬁcant two-sample MR ﬁndings, in
sensitivity analyses, we further conducted leave-one-out analyses, MR using
sleep duration effect estimates adjusting for standard confounders including
BMI, insomnia, and other lifestyle factors, and restricted to those GWAS var-
iants from each respective analysis, MR restricted to the signals that retained
GWAS signiﬁcance in meta-analysis, and lastly, reverse direction MR analysis.
For reverse direction MR, inverse variance weighted MR causal effect estimates
in minutes were ﬁrst converted to hours by multiplying by 60, and then were
converted by multiplying by 0.693 (=ln(2)) in order to represent changes in
sleep duration in hours per doubling in odds of the binary exposure. The
number of SNPs used in each MR analysis varies by outcome because of some
SNPs (or proxies for them) not being located in the outcome GWAS. In addition,
for schizophrenia MR, we excluded two pleiotropic SNPs rs34556183 (near
HIST1H2BJ) and rs13109404 (near SLC39A8) from our analysis and, to test for
bidirectional links, we derived the schizophrenia instrumental variable using
GWAS variants reported by the Psychiatric Genomics Consortium Schizo-
phrenia working group73.
Data availability
Summary GWAS statistics are publicly available at the Sleep Disorder Knowledge Portal
(http://sleepdisordergenetics.org/) and the UK Biobank website (http://biobank.ctsu.ox.
ac.uk/).
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